Published in
Springer (part of Springer Nature), Breast Cancer Research and Treatment, 1(146), p. 153-162
DOI: 10.1007/s10549-014-3015-6
Links
Tools
Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study
Journal article published in 2014 by
Mark J. Clemons,
Brandy Cochrane,
Gregory R. Pond,
Nadia Califaretti,
Stephen K. L. Chia,
Rebecca Alexandra Dent,
Xinni Song,
Andre Robidoux,
Sameer Parpia,
David Warr,
Daniel Rayson,
Kathleen I. Pritchard,
Mark N. Levine
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 